[1]
Ravasio, R., Antonelli, S., Maiorino, A., Costanzo, A. and Losi, S. 2019. Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Global and Regional Health Technology Assessment. 6, 1 (Jan. 2019). DOI:https://doi.org/10.33393/grhta.2019.468.